Biotech’s peanut allergy debate might be over
Back in early 2018, there were three oft-discussed biotech companies vying to come up with a treatment for kids with peanut allergies. Disappointing data led investors to dismiss one, called AnaptysBio. Another, Aimmune Therapeutics, saw some discouraging side effects with its therapy but managed to convince the FDA to approve it this year. As of this week, DBV Therapeutics, a third, was on its way toward FDA approval with an approach it believes to be superior.
But that might have just gone off the rails. Yesterday, DBV said the FDA canceled a planned advisory meeting after identifying “questions regarding efficacy” when it comes to the company’s product, a skin patch meant to gradually decrease allergy. As it stands, the FDA’s promised decision date of Aug. 5 hasn’t changed, but if DBV has to submit more data, it almost certainly will.
To investors, that signaled the end of DBV’s hopes of competing with Aimmune. The company’s share price fell nearly 60% after hours, while Aimmune’s rose 26%.
But that might have just gone off the rails. Yesterday, DBV said the FDA canceled a planned advisory meeting after identifying “questions regarding efficacy” when it comes to the company’s product, a skin patch meant to gradually decrease allergy. As it stands, the FDA’s promised decision date of Aug. 5 hasn’t changed, but if DBV has to submit more data, it almost certainly will.
To investors, that signaled the end of DBV’s hopes of competing with Aimmune. The company’s share price fell nearly 60% after hours, while Aimmune’s rose 26%.
.png)
No hay comentarios:
Publicar un comentario